CRVS - Corvus Pharmaceuticals: Undervalued Based On COVID-19 Opportunity And Oncology Assets
- Corvus is a small biotech targeting the adenosine cancer pathway with two assets in clinical development, with a credible path to approval for its A2A Receptor Antagonist.
- The company is prioritizing development of its CD73 candidate, CPI-006 as a COVID-19 treatment and hopes to initiate a pivotal Phase 3 trial this year based on solid data.
- Shares trade at $3.7 and Corvus' market cap is just $104m, despite its diversified portfolio of assets.
- An experienced management team adds weight to the thesis that the company may be significantly undervalued.
- With little cash, a development partner would be welcome. That may happen, and with multiple data catalysts in 2021, Corvus is a potentially Strong Buy for risk-on investors.
For further details see:
Corvus Pharmaceuticals: Undervalued Based On COVID-19 Opportunity And Oncology Assets